- Home
- MLKN vs KROS Comparison
MLKN vs KROS Comparison
Compare MLKN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLKN
- KROS
- Stock Information
- Founded
- MLKN 1905
- KROS 2015
- Country
- MLKN United States
- KROS United States
- Employees
- MLKN N/A
- KROS N/A
- Industry
- MLKN Office Equipment/Supplies/Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- MLKN Consumer Discretionary
- KROS Health Care
- Exchange
- MLKN Nasdaq
- KROS Nasdaq
- Market Cap
- MLKN 2.0B
- KROS 1.8B
- IPO Year
- MLKN N/A
- KROS 2020
- Fundamental
- Price
- MLKN $26.87
- KROS $52.51
- Analyst Decision
- MLKN Hold
- KROS Strong Buy
- Analyst Count
- MLKN 1
- KROS 5
- Target Price
- MLKN $25.00
- KROS $93.40
- AVG Volume (30 Days)
- MLKN 336.3K
- KROS 320.2K
- Earning Date
- MLKN 09-19-2024
- KROS 11-04-2024
- Dividend Yield
- MLKN 2.79%
- KROS N/A
- EPS Growth
- MLKN 101.82
- KROS N/A
- EPS
- MLKN 1.11
- KROS N/A
- Revenue
- MLKN $3,628,400,000.00
- KROS $271,000.00
- Revenue This Year
- MLKN $3.21
- KROS $3,423.84
- Revenue Next Year
- MLKN $4.46
- KROS $19.85
- P/E Ratio
- MLKN $24.21
- KROS N/A
- Revenue Growth
- MLKN N/A
- KROS N/A
- 52 Week Low
- MLKN $16.50
- KROS $27.02
- 52 Week High
- MLKN $31.73
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- MLKN 37.06
- KROS 64.92
- Support Level
- MLKN $28.78
- KROS $44.59
- Resistance Level
- MLKN $29.78
- KROS $55.01
- Average True Range (ATR)
- MLKN 0.72
- KROS 2.56
- MACD
- MLKN -0.27
- KROS 0.96
- Stochastic Oscillator
- MLKN 3.15
- KROS 76.36
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract , International Contract & Specialty International & Specialty and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.